ASCO big coffee interpretation | Professor Zhou Cun: achieve higher deep relief, the front line of Boginib helps ALK positive late NSCLC patients to comprehensively benefit

*For medical professionals for reading reference

The basis for the benefit of the first -line therapy of Boginib can be further consolidated!

In non -small cell lung cancer (NSCLC), about 3%to 5%of NSCLC patients have mutations of inter -alter lymphomin kinase (ALK) genes. In recent years, targeted therapy for ALK targets has developed rapidly. At present, there are many ALK tyrosine kinase inhibitors (ALK-TKI). It is rich, but the first-line treatment option of ALK-positive NSCLC is still the problem that clinicians are concerned [1-2].

In the 2022 U.S. Clinical Oncology Society (ASCO) Conference, Berutini two first-line therapy related studies ALTA-1L research exploration analysis and J-Alta research appeared on the stage in the form of wall newspaper (Abstract number: 9072, 9075) to further show The excellent efficacy of Buerkeni in the first line of treatment.

Based on this, the "Medical Circular Cancer Channel" invited Professor Zhou Cun, a professor of Shanghai Lung Department of Tongji University, to share the efficacy and clinical significance of the first -line treatment of Bigetinib.

Bigtinib first -line treatment advantage: strong brain protection is better survive

Professor Zhou Cun first introduced: "Butgininib is the second generation of powerful selectivity Alk-TKI. The alta-1L study shows that Pogkinib has been fully sufficient in extending patients' survival, controlling brain metastases, and improving the quality of life. The advantage of verification, the first line of the Boginib brought a comprehensive benefit for the ALK -positive NSCLC. "

Specific relief -the overall population is more than the 30 -month mark of PFS

Regarding the efficacy of Buerginib, Professor Zhou Cun talked: "The key III clinical study of the key III-Alta-1L research head opposite comparison of the treatment of antibagininib and cizinini 1 line, ALK-TKI's unprecedented local advanced or metastatic NSCLC patients' efficacy and safety. The results show that the median no progressive survival (PFS) of Boginib therapy in the overall population is as high as 30.8 months (PFS) (PFS) INV), a significant reduction in the progress of the disease or the risk of death of 57%[3]. "

Alta-1L Study: Pogkinib curative effect data

Strong brain -patients with baseline brain metastasis 4 years OS rate is as high as 71%

Professor Zhou Cun said: "ALK -positive late NSCLC patients are prone to brain metastases, and Pogntinib also has excellent effect on brain metastases -the median PFS of the first -line treatment of baseline brain metastases in the first -line therapy of Bigetini reaches 24.0 months (in contrast The group is 5.6 months), which has reduced the risk of disease progress or death by 75%. The total survival (OS) rate of 4 years is as high as 71%[3-5]. Boginib brought inspirational long-term patients with brain metastases. Benefiting from survival. "

Patients with brain metastases benefit in the treatment of Pogkinib

A better survival -the first ALK TKI to achieve a significant benefit of survival and life

Professor Zhou Cun added: "Boginib's treatment related adverse reactions are mostly mild, and adverse reactions above level 3 are mostly bloody biochemical indicators. Most patients are asymptomatic."

Pogkininib (blue) and Kizibinib (gray) first -line treatment safety data

Professor Zhou Cun recognizes that not only will patients live longer, but also live better. In terms of quality of life, the first-line treatment of Pogkinini has significantly improved the quality of life of patients than clipininib. It is the first ALK-TKI in improved or maintained the quality of life in patients to improve or maintain the quality of life. [3].

The first -line therapy of Boginib provides comprehensive benefits for patients, and fully establishes its status in the first -line treatment of advanced NSCLC in ALK.

In-depth relief, Asia benefits, Asco's latest data once again consolidates the front-line advantage of Boginib, an analysis of the first-line advantage of the Berginini

Professor Zhou Cun introduced: "In the evaluation indicators of the efficacy evaluation, the depth reflects the degree of tumor shrinking. The previous relief of depth and curative effects has been reflected in the treatment of lung cancer ALK pathway and other cancer species [6-7]."

According to the results of the exploration analysis of Alta-1L in ASCO, Professor Zhou Cun said: "The proportion of patients with higher in-depth relieving patients than Knitininib (reduction of target lesions is> 75%), and the Bogkinib group The proportion of patients in the in -depth relief in the Kizotinib group is 56%and 34%(P = 0.0005), respectively. And the study found that the deep relief of the target lesion is related to the better treatment ending of the patient -the median PFS of the patient in the depth relief group As high as 44.1 months, and the 3-year OS rate is as high as 85%, the ALTA-1L exploration analysis once again confirms the excellent efficacy of Pognib on the front line [8]. "

Alta-1L exploration simply analysis results

J-Alta Research-Asian first-line data once again consolidated the position of the first-line treatment of Boginib

Professor Zhou Cun introduced: "J-Alta Research is an inquiring about the efficacy and safety single arm, multi-center, and open label research in Pogkini in Japan ALK positive NSCLC patients. The first -line data of the first treatment of the first treatment of ALK+NSCLC in the treatment of Ni. The results show that in the TKI initial treatment queue, the first -line therapy of the Pogkinib provides a significant PFS benefit for the patient. The rate is as high as 73%. It is worth noting that the ORR of the first-line treatment of Boginib is as high as 97%, and the relief rate of more than 90%is relatively rare in ALK-TKI related studies. The excellent efficacy of Donny on the front line [9]. "

J-Alta Research Data

Professor Zhou Cun added: "I hope that in the future, Chinese experts can accumulate the application experience of Pogkinib clinically. If the results of the curative effect in the J-Alta study can be re-enjoined, it means that Pogkinib will become my country's ALK-positive NSCLC in China. One of the new standards for patients' first treatment. "

Provide diverse treatment options, and Bigetini will benefit more patients in the medical insurance

Professor Zhou Cun concluded: "1 to 2 years after the treatment of EGFR and other targets will progress. The treatment time of ALK-positive NSCLC patients is relatively long, which is closer to the management of" slow disease ". Patients use ALK- TKI treatment may reach 30 months. Therefore, the price of drugs has a great impact on the compliance of patient treatment. Patients with economic difficulties may miss the opportunity to treat the most suitable drugs for treatment. "

In the end, Professor Zhou Cun called for: "If Boginib can enter medical insurance, it will further improve the availability of the drug and benefit more patients. Therefore, we hope that Poginib can be included in the reimbursement scope of medical insurance as soon as possible to reduce patients with patients The possibility of poverty caused by illness and returning to poor due to illness, so as to benefit more patients. "

Expert Introduction

Professor Zhou Cun

Shanghai Lung Department, Affiliated to Tongji University

Executive Member of the China Clinical Oncology Society

Chairman of the Chinese Medical Promotion Association's chest tumor branch

IASLC BOD

Chairman of the Non -Small Cell Special Committee of the China Clinical Oncology Society

Standing Committee Member of the China Anti -Cancer Association Lung Cancer Professional Committee

Deputy Chairman of the Shanghai Anti -Cancer Association

Chairman of the Shanghai Anti -Cancer Association Pulmonary Cancer Molecular targeted and immunotherapy

Deputy Chairman of the Professional Committee of Cancer Association of the China Anti -Cancer Association

Standing Committee Member of the Chinese Medical Association Tumor Branch

Vice President of the Tumor Branch of the Shanghai Medical Association

Deputy Chairman of the Tumor Branch of the Shanghai Medical Association

Director of the Institute of Cancer Institute of Tongji University Medical College

Shanghai leader

For medical professionals only

Approval number: C-Aprom/CN/ALUN/0192 Approval Date: August 2022

references

[1]. China Clinical Oncology Society Working Committee. China Clinical Oncology Society (CSCO) non-small cell carcinoma diagnosis and treatment guide 2021 [M]. People's Health Publishing House, 2021: 107-110.

[2]. Zhang Xunchao, Lu Shun, Tension, etc. The diagnosis and treatment guide of transgender lymphoma kinase (ALK) in China [J]. Chinese Pathological Magazine. 2015,44 (10): 696-703.

[3]. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial[J]. J Thorac Oncol . 2021 Dec; 16 (12): 2091-2108.

J clin oncol. 2020 nov 1; 38 (31): 3592-3603. [5] .Camidge Dr, Kim HR, Ahn MJ, et al. Brigatinib versususususus in alk-POSITIVE NON-SMALL LUNG CANCER [J]. N English J Med. 2018 nov22; 379 (21): 2027-203

[8] .camidge drr, et al. ASCO 2022. Abstract 9072.

[9]. Kumagai T, et al. ASCO 2022. Abstract 9075.

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -